



GOLDEN MEDITECH HOLDINGS LIMITED
金衛醫療集團有限公司

【For Immediate Release】

GOLDEN MEDITECH COMPLETES SALE OF EQUITY INTEREST IN CHINA CORD BLOOD CORPORATION

Hong Kong, 31 January 2018 – Golden Meditech Holdings Limited (SEHK stock code: 00801) (the "Company"), a leading integrated healthcare enterprise in China, is pleased to announce that the sale of 65.4% of the issued share capital of China Cord Blood Corporation to Nanjing Yingpeng Huikang Medical Industry Investment Partnership (Limited Partnership)* (南京盈鵬蕙康醫療產業投資合夥企業(有限合夥)) has been completed.

Details have been published by the Company in accordance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and posted on the Company's website as follows: <http://www.goldenmeditech.com/eng/ir/announcements.php?year=2018>

– End –

About Golden Meditech Holdings Limited (SEHK stock code: 00801)

Golden Meditech (www.goldenmeditech.com) is a leading integrated-healthcare enterprise in China. It is a first-mover in China, having established its dominant positions in several markets including the medical devices market and the hospital management market in the healthcare industry, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, Golden Meditech will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

For inquiries, please contact:

Investor Relations Department
Golden Meditech Holdings Limited
Tel: (852) 3605 8180
Fax: (852) 3605 8181
Email: ir@goldenmeditech.com

* For identification purpose only.